


PHARMACEUTICAL 2017

ALDER BIOPHARMACEUTICALS INC Rank 33 of 292





PHARMACEUTICAL 2017



ALDER BIOPHARMACEUTICALS INC Rank 33 of 292

The relative strengths and weaknesses of ALDER BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALDER BIOPHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of ALDER BIOPHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 231%, being 228% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	393,183
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,890
Liabilities, Non-Current	0
Other Assets	8,895
Other Compr. Net Income	453
Other Expenses	113
Other Liabilities	481
Other Net Income	2,767
Other Revenues	0
Property and Equipment	7,076
Research and Development	132,760
Selling, General and Administrative Expense	26,148

Output Variable	Value in 1000 USD
Assets	409,154
Liabilities	26,371
Expenses	159,021
Revenues	0
Stockholders Equity	382,783
Net Income	-156,254
Comprehensive Net Income	-156,028
Economic Capital Ratio	231%

